Treatment Program for Anemia in AIDS Patients

Johnson & Johnson (J&J)

Status: Completed

Conditions: Cytopenias; HIV Infections

Treatments: Drug: Epoetin alfa

Study type: Interventional

Funder types: Industry

Identifiers

NCT00002022

I88-083

004G

Details and patient eligibility

About

The objective of the Eprex (erythropoietin) Treatment Program is to provide erythropoietin for the treatment of anemia in AIDS patients.

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Life expectancy < 3 months.
• = or < grade 4 performance score.
• AIDS-related dementia.
• Uncontrolled hypertension.
• Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients with the following are excluded:

• Life expectancy < 3 months.
• = or < grade 4 performance score.
• AIDS-related dementia.
• Uncontrolled hypertension.
• Acute symptomatic opportunistic infection or other AIDS-defining illness.

Patients must have:

• A clinical diagnosis of AIDS.
• Hematocrit < 30 percent.
• Endogenous serum erythropoietin level = or < 500 U/ml.
• A life expectancy = or > 3 months.
• > Grade 4 performance score.